1
|
Norgren L, Hiatt WR, Dormandy JA, Nehler
MR, Harris KA, Fowkes FG; TASC II Working Group; Bell K, Caporusso
J, Durand-Zaleski I, et al: Inter-Society consensus for the
management of peripheral arterial disease (TASC II). Eur J Vasc
Endovasc Surg. 33:(Suppl 1). S1–S75. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Hernando FJ Serrano and Martín Conejero A:
Peripheral artery disease: Pathophysiology, diagnosis and
treatment. Rev Esp Cardiol. 60:969–982. 2007.(In Spanish).
PubMed/NCBI
|
3
|
Mahameed AA: Peripheral arterial disease.
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/peripheral-arterial-disease/Accessed.
January 11–2009.
|
4
|
Kullo IJ and Leeper NJ: The genetic basis
of peripheral arterial disease: Current knowledge, challenges, and
future directions. Circ Res. 116:1551–1560. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Chen XP and Du GH: Lectin-like oxidized
low-density lipoprotein receptor-1: Protein, ligands, expression
and pathophysiological significance. Chin Med J (Engl).
120:421–426. 2007.PubMed/NCBI
|
6
|
Arjuman A and Chandra NC: Effect of IL-10
on LOX-1 expression, signaling and functional activity: An
atheroprotective response. Diab Vasc Dis Res. 10:442–451. 2013.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Tesmer LA, Lundy SK, Sarkar S and Fox DA:
Th17 cells in human disease. Immunol Rev. 223:87–113. 2008.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Taleb S, Tedgui A and Mallat Z: Adaptive T
cell immune responses and atherogenesis. Curr Opin Pharmacol.
10:197–202. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Madhur MS, Lob HE, McCann LA, Iwakura Y,
Blinder Y, Guzik TJ and Harrison DG: Interleukin 17 promotes
angiotensin II-induced hypertension and vascular dysfunction.
Hypertension. 55:500–507. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Zhang X, Pei F, Zhang M, Yan C, Huang M,
Wang T and Han Y: Interleukin-17A gene variants and risk of
coronary artery disease: A large angiography-based study. Clin Chim
Acta. 412:327–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Mai J, Nanayakkara G, Lopez-Pastrana J, Li
X, Li YF, Wang X, Song A, Virtue A, Shao Y, Shan H, et al:
Interleukin-17A promotes aortic endothelial cell activation via
transcriptionally and post-translationally activating p38
mitogen-activated protein kinase (MAPK) pathway. J Biol Chem.
291:4939–4954. 2016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Biocca S, Falconi M, Filesi I, Baldini F,
Vecchione L, Mango R, Romeo F, Federici G, Desideri A and Novelli
G: Functional analysis and molecular dynamics simulation of LOX-1
K167N polymorphism reveal alteration of receptor activity. PLoS
One. 4:e46482009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Tatsuguchi M, Furutani M, Hinagata J,
Tanaka T, Furutani Y, Imamura S, Kawana M, Masaki T, Kasanuki H,
Sawamura T and Matsuoka R: Oxidized LDL receptor gene (OLR1) is
associated with the risk of myocardial infarction. Biochem Biophys
Res Commun. 303:247–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
14
|
Hou XW, Wang LF, Wang N, Pang D, Hui B,
Zhou YL and He X: The G501C polymorphism of oxidized LDL receptor
gene [OLR-1] is associated with susceptibility and serum C-reactive
protein concentration in Chinese essential hypertensives. Clin Chim
Acta. 388:200–203. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Hattori H, Sonoda A, Sato H, Ito D,
Tanahashi N, Murata M, Saito I, Watanabe K and Suzuki N: G501C
polymorphism of oxidized LDL receptor gene (OLR1) and ischemic
stroke. Brain Res. 1121:246–249. 2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang J, Yin C, Zhang Y, Zhao L, Fu H and
Feng J: The role of OLR1 polymorphisms in determining the risk and
prognosis of ischemic stroke in a Chinese population.
NeuroRehabilitation. 32:391–396. 2013.PubMed/NCBI
|
17
|
Liu X, Zhu RX, Li L and He ZY: Association
of LOX-1 gene polymorphisms with cerebral infarction in northern
Chinese Han population. Lipids Health Dis. 13:552014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Libby P, Ridker PM and Maseri A:
Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Dunn S, Vohra RS, Murphy JE,
Homer-Vanniasinkam S, Walker JH and Ponnambalam S: The lectin-like
oxidized low-density-lipoprotein receptor: A pro-inflammatory
factor in vascular disease. Biochem J. 409:349–355. 2008.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Liuzzo G, Trotta F and Pedicino D:
Interleukin-17 in atherosclerosis and cardiovascular disease: The
good, the bad, and the unknown. Eur Heart J. 34:556–559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Lim H, Kim YU, Sun H, Lee JH, Reynolds JM,
Hanabuchi S, Wu H, Teng BB and Chung Y: Proatherogenic conditions
promote autoimmune T helper 17 cell responses in vivo. Immunity.
40:153–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Goyal T, Mitra S, Khaidakov M, Wang X,
Singla S, Ding Z, Liu S and Mehta JL: Current concepts of the role
of oxidized LDL receptors in atherosclerosis. Curr Atheroscler Rep.
2012.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
24
|
Hansson GK and Hermansson A: The immune
system in atherosclerosis. Nat Immunol. 12:204–212. 2011.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Gao S and Geng YJ: LOX-1: A male
hormone-regulated scavenger receptor for atherosclerosis. Vascul
Pharmacol. 59:138–143. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Fukui M, Tanaka M, Senmaru T, Nakanishi M,
Mukai J, Ohki M, Asano M, Yamazaki M, Hasegawa G and Nakamura N:
LOX-1 is a novel marker for peripheral artery disease in patients
with type 2 diabetes. Metabolism. 62:935–938. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Ding Z, Mizeracki AM, Hu C and Mehta JL:
LOX-1 deletion and macrophage trafficking in atherosclerosis.
Biochem Biophys Res Commun. 440:210–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Au A, Griffiths LR, Cheng KK, Wee Kooi C,
Irene L and Wei L Keat: The influence of OLR1 and PCSK9 gene
polymorphisms on ischemic stroke: Evidence from a meta-analysis.
Sci Rep. 5:182242015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Potekhina AV, Pylaeva E, Provatorov S,
Ruleva N, Masenko V, Noeva E, Krasnikova T and Arefieva T:
Treg/Th17 balance in stable CAD patients with different stages of
coronary atherosclerosis. Atherosclerosis. 238:17–21. 2015.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Madhur MS, Funt SA, Li L, Vinh A, Chen W,
Lob HE, Iwakura Y, Blinder Y, Rahman A, Quyyumi AA and Harrison DG:
Role of interleukin 17 in inflammation, atherosclerosis, and
vascular function in apolipoprotein e-deficient mice. Arterioscler
Thromb Vasc Biol. 31:1565–1572. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Ge S, Hertel B, Koltsova EK,
Sörensen-Zender I, Kielstein JT, Ley K, Haller H and von
Vietinghoff S: Increased atherosclerotic lesion formation and
vascular leukocyte accumulation in renal impairment are mediated by
interleukin-17A. Circ Res. 113:965–974. 2013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Rao LN, Ponnusamy T, Philip S,
Mukhopadhyay R, Kakkar VV and Mundkur L: Hypercholesterolemia
induced immune response and inflammation on progression of
atherosclerosis in Apob(tm2Sgy) Ldlr(tm1Her)/J mice. Lipids.
50:785–797. 2015. View Article : Google Scholar : PubMed/NCBI
|
33
|
Vargas-Alarcón G, Angeles-Martínez J,
Villarreal-Molina T, Alvarez-León E, Posadas-Sánchez R,
Cardoso-Saldaña G, Ramírez-Bello J, Pérez-Hernández N, Juárez-Rojas
JG, Rodríguez-Pérez JM, et al: Interleukin-17A gene haplotypes are
associated with risk of premature coronary artery disease in
Mexican patients from the Genetics of Atherosclerotic Disease (GEA)
study. PLoS One. 10:e01149432015. View Article : Google Scholar : PubMed/NCBI
|